Sarepta Therapeutics (SRPT) has drawn fresh attention after filing a US$39.7 million shelf registration tied to an employee stock ownership plan, alongside appointing Michael Severino, M.D., as its new Chief Executive Officer. See our latest analysis for Sarepta Therapeutics. The CEO transition and fresh equity capacity come after a period where Sarepta Therapeutics’ share price has fallen 30.9% over the past three months and 30.3% year to date, while the 3 year total shareholder return is...

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

No description provided for this story.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has been given a consensus rating of "Hold" by the twenty-one analysts that are covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation a

No description provided for this story.

No description provided for this story.

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (NASDAQ:SRPT) will be releasing its Q2 2026 earnings after the market closes on Wednesday, August 5. (View Earnings Report at

Healthcare of Ontario Pension Plan Trust Fund decreased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 23.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 365,329 shares of the biotechnology co

No description provided for this story.

Some five months after announcing the planned retirement of its longtime CEO Doug Ingram over what the helmsman dubbed an “ironic twist of fate” involving the health of his family members, Sarepta Therapeutics has found a permanent replacement.

Morgan Stanley said it remains cautious in the near term because of continued challenges in the company's Duchenne muscular dystrophy business.

The beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO. Sarepta Therapeutics, the bruised maker of Duchenne muscular dystrophy treatments, on Monday named Michael Severino, formerly the CEO of Tessera Therapeutics, as its new chief executive, starting Tuesday. Severino is replacing Doug Ingram, who announced earlier this year that he planned to retire after leading the biotech for nearly a decade. During his tenure, the company got three Duchenne treatments approved, but has faced ongoing questions about how effective they are and run into regulatory scrutiny over the safety of its gene therapy. The company’s share price has tanked from where it was at the beginning of 2025.Continue to STAT+ to read the full story…

No description provided for this story.

No description provided for this story.

Sarepta Therapeutics appoints Dr. Michael Severino as CEO starting July 2026, signaling a strategic leadership shift with expertise from AbbVie and Tessera Therapeutics. The company aims to continue expanding its portfolio in genetic medicine as Severino succeeds Doug Ingram, who is set to retire after notable growth and innovation milestones.

CAMBRIDGE, Mass., July 27, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors. Severino succeeds Doug Ingram, who is retiring and will serve the company in an advisory capacity until the end of 2026 to ensure a smooth transition.

No description provided for this story.

With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.

No description provided for this story.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, Aug. 5, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.

In June 2026, Sarepta Therapeutics announced that the FDA accepted supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy exon-skipping therapies AMONDYS 45 and VYONDYS 53 to traditional approvals, with a PDUFA action date set for February 28, 2027. This move, backed by the ESSENCE confirmatory study and extensive real-world evidence across more than 1,800 treated patients, could be important for reinforcing the long-term regulatory footing of...

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall. The post Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout appeared first on 24/7 Wall St.. Moderna (MRNA) down 11% to $68.42, ImmunityBio (IBRX) down 8% to $8.15, Sarepta (SRPT) down 7% to $19.02 amid sector-wide profit-taking after 2026 gains. Moderna's bull case depends on August PDUFA flu vaccine decision and $4.5B–$5B year-end cash target; bear case cites 67% five-year decline and $1.34B net loss. ImmunityBio's 348% YTD run reflects Russell 1000 inclusion hopes and ANKTIVA strength; Q1 2026 revenue of $44.21M surged 168% year-over-year, yet sector rotation pressures persist. Sarepta received Wolfe Research Outperform upgrade with $27 target (34% upside), but biotech rotation favors defensive names like Eli Lilly (LLY) and J&J (JNJ). This lithium producer surpassed a $1B private valuation, joining some of America’s most powerful startups. Now you can invest in EnergyX alongside global giants like General Motors, but only through July 16. (sponsor) Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run. Moderna (NASDAQ:MRNA) stock is down 11% to $68.50, ImmunityBio (NASDAQ:IBRX) shares are off 8% to $8.16, and Sarepta Therapeutics (NASDAQ:SRPT) stock has slid 8% to $18.84. The moves are steep, but they land on top of extraordinary year-to-date gains. Moderna stock had climbed 160% year to date through Thursday’s close, and ImmunityBio shares were up 348% year to date heading into today. There’s no company-specific bad news attached to any of the three names. The SPDR S&P Biotech ETF (NYSEARCA:XBI) is off 4% midday, framing this as a sector-wide flush rather than a single-name blowup. The equal-weighted sector proxy holds all three of today’s decliners among its constituents. Profit-Taking After a Parabolic Run The cleanest read on today’s selloff in Moderna, ImmunityBio, and Sarepta and other biotechnology stocks is profit-taking and sector rotation after a parabolic run. Recent news flow on all three names was actually bullish, and no headline catalyst has surfaced to explain the move. ImmunityBio has ridden Russell 1000 inclusion hopes and Anktiva optimism to its triple-digit gain, with Q1 2026 revenue of $44.21 million up 168% year over year and ANKTIVA unit sales up 168% year over year. Sarepta Therapeutics stock, meanwhile, was just upgraded by Wolfe Research to Outperform with a $27 target, implying 34% upside from Thursday’s close. Moderna’s own Q1 2026 print was strong: revenue of $389 million beat the consensus estimate by 65%, and management reaffirmed up to 10% revenue growth for the year. The near-term catalyst is the mRNA-1010 seasonal flu vaccine PDUFA date of August 5. Big Pharma Barely Flinches The rotation angle sharpens when you look outside biotech. Eli Lilly (NYSE:LLY) stock is down 3% midday, while Johnson & Johnson (NYSE:JNJ) shares are off by just 1%. That gap tells the story. Money is coming out of high-beta, pre-profit biotech names and holding still in defensive large-cap pharma, where Eli Lilly stock is still up 10% year to date and Johnson & Johnson stock is up 24% year to date. XBI Puts the Selloff in Perspective The SPDR S&P Biotech ETF is the cleanest sector proxy since it holds Moderna, ImmunityBio, and Sarepta among its equal-weighted constituents. Even after today’s drop, XBI is still up 78% over the past 12 months. Because the ETF is equal-weighted, its move reflects broad biotech weakness rather than one name driving the move. The fund isn’t leveraged, but it is a volatile sector vehicle, and today’s action is a reminder of how quickly biotech beta cuts both ways. Moderna: Bull Case Meets Bear Case The bull case for Moderna leans on the pipeline. The August PDUFA on the flu vaccine, brands including Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX, and a year-end cash target of $4.5 billion to $5 billion give management runway. Reddit retail sentiment sits at 72, classified as bullish, framing the run as a “savage comeback” comparable to post-dotcom recovery. The bear case is the price action. Moderna stock is down 71% over five years, cash burn remains heavy after a $1.34 billion GAAP net loss, and consensus analyst targets sit well below the current price. Investors may want to size their positions modestly given the high-beta profile visible in today’s move. What to Watch Next The immediate tell is whether XBI stabilizes into the close or accelerates lower, which would signal the rotation has more room to run. Moderna’s August 5 PDUFA decision is the next hard-dated catalyst on the calendar for the primary name. The takeaway: today’s slide in Moderna, ImmunityBio, and Sarepta looks like an unwind after a historic biotech rally rather than a fundamental rerating. Investors holding these names may want to reassess their position sizing given how quickly a sharp one-month gain in Moderna can compress into a double-digit down day. Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16. Over 50,000 people already have, along with global giants like General Motors and POSCO. Here’s why there’s so much interest: EnergyX’s patented tech can recover up to 3X more lithium than traditional methods. That’s a big deal, as demand for lithium is expected to 5X current production levels by 2040.Become an early-stage EnergyX shareholder before the 7/16 investment deadline. The post Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout appeared first on 24/7 Wall St..

A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price decreased by analysts at Piper Sandler from $23.00 to $20.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Piper Sandler’s price objective indicates a potential downside of 1.46% from the company’s […]

Zacks Research lowered Sarepta Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday.

Louisiana State Employees Retirement System purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 46,500 shares of the biotechnology company’s stock, valued at approximately $1,012,000. Several other institutional investors […]

Sarepta is seeking full approval for Amondys 45 and Vyondys 53 in Duchenne muscular dystrophy.

Proposed text: CureDuchenne was an early funder of Sarepta Therapeutics, and we are pleased to share that the US FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45 […] The post FDA accepts Sarepta’s application to convert AMONDYS 45 and VYONDYS 53 from accelerated to full approval appeared first on CureDuchenne. Proposed text: CureDuchenne was an early funder of Sarepta Therapeutics, and we are pleased to share that the US FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45 and VYONDYS 53, for individuals with Duchenne amenable to skipping exon 45 and exon 53, respectively. The FDA is targeting a PDUFA decision date of February 28, 2027. If successful, this would convert the accelerated approvals of these two drugs to traditional approvals. Sarepta has indicated that these applications include data from the ESSENCE confirmatory study, published real-world evidence, and considerable safety data. Press release:

Sarepta Therapeutics' (SRPT) Elevidys for Duchenne muscular dystrophy shows near-term stabilization,

No description provided for this story.

Sarepta Therapeutics recently filed a US$341.99 million shelf registration for 7,786,841 common shares tied to employee stock ownership, alongside shareholder approval of new 2026 equity incentive and employee stock purchase plans. This combination of fresh equity capacity and ESOP-related issuance highlights Sarepta’s focus on funding growth and retaining talent while preserving balance sheet flexibility. With Sarepta returning to profitability in the first quarter of 2026, we’ll now...

No description provided for this story.

Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SRPT vs. ARGX: Which Stock Is the Better Value Option?

BNP Paribas Financial Markets trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 59.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 727,786 shares of the biotechnology company's stock after selling 1,05

No description provided for this story.

No description provided for this story.

No description provided for this story.

No description provided for this story.

No description provided for this story.

No description provided for this story.

No description provided for this story.

No description provided for this story.

No description provided for this story.

No description provided for this story.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stands as a pivotal player in the biotechnology industry, with a strong focus on the development of RNA-targeted therapeutics and gene therapy for rare diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s innovative work primarily targets Duchenne muscular dystrophy (DMD), a rare genetic disorder. The company has brought to market several key […] Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stands as a pivotal player in the biotechnology industry, with a strong focus on the development of RNA-targeted therapeutics and gene therapy for rare diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s innovative work primarily targets Duchenne muscular dystrophy (DMD), a rare genetic disorder. The company has brought to market several key therapies, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, which cater to specific genetic mutations in patients with DMD, as well as ELEVIDYS, a gene therapy with specific contraindications. Currently, Sarepta’s stock is priced at $17.87, following a slight increase of 0.03% in the recent trading session. This places the stock in the lower end of its 52-week range of $11.93 to $43.01, offering a potentially attractive entry point for investors, particularly given the average target price of $22.00 set by analysts, indicating a potential upside of 23.11%. Despite the company’s market cap of $1.89 billion, Sarepta presents a mixed bag of financial metrics. The company has not reported a trailing P/E ratio, and forward P/E is relatively low at 6.56, suggesting that the market may be undervaluing its future earnings potential. However, revenue growth has slipped by 1.90%, which could be a concern for growth-focused investors. The company’s EPS stands at 0.35, and the Return on Equity is a modest 4.91%, reflecting the challenges in the competitive biotech sector. Sarepta’s free cash flow is a notable $204.78 million, providing a solid foundation for ongoing research and development activities. The absence of a dividend yield underscores the company’s reinvestment strategy, typical of biotech firms focusing on innovation and long-term success rather than immediate income distribution. Analyst sentiment on Sarepta is varied, with 6 buy ratings, 13 hold ratings, and 5 sell ratings. The mixed analyst ratings reflect both the potential and the risks inherent in the biotech sector, where clinical trial outcomes and regulatory decisions can significantly impact stock performance. Technical indicators reveal a challenging landscape for Sarepta’s stock. The current price is below both the 50-day and 200-day moving averages, at $20.08 and $19.96 respectively, while the RSI (Relative Strength Index) at 19.87 indicates the stock is in oversold territory. The MACD (Moving Average Convergence Divergence) and signal line both suggest bearish momentum, with values of -0.97 and -0.89, respectively. Sarepta’s robust pipeline, which includes promising therapies like SRP-9003 for LGMD2E and SRP-1001 and SRP-1003 in early-phase trials, points to significant future potential. Strategic collaborations with industry leaders such as F. Hoffman-La Roche Ltd and partnerships with renowned institutions like Duke University further bolster the company’s credibility and innovative capacity. Investors considering Sarepta Therapeutics, Inc. should weigh the company’s strong market position in gene therapy and RNA-targeted therapeutics against the inherent risks of the biotech sector, including clinical trial uncertainties and regulatory hurdles. The stock’s current valuation, combined with its technical indicators and analyst ratings, suggests a cautious yet potentially rewarding opportunity for those with a long-term investment horizon.